Business Context and Reporting Period
This Form 8-K is a current report filed by ReWalk Robotics Ltd. on April 5, 2016. The filing discloses corporate governance changes regarding the Board of Directors and the Audit Committee. The registrant is incorporated in Israel and maintains its principal executive offices in Yokneam Ilit, Israel.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and associated compensation arrangements rather than operational financial performance.
Material Changes
- Board Resignation: Jay Kalish resigned from the Board of Directors and the Audit Committee effective April 5, 2016. Mr. Kalish had served as an interim member while the Company searched for a permanent appointee.
- Board Appointment: Peter L. Wehrly was appointed as a Class I director and a member of the Audit Committee effective April 5, 2016. His term extends until the 2018 annual meeting of shareholders.
- Independence Determination: The Board determined that Mr. Wehrly satisfies SEC and Nasdaq independence requirements and is financially literate under Rule 10A-3(b)(1).
Guidance, Outlook, and Compensation
The filing contains no guidance, outlook, or management commentary regarding future financial performance or risks. It details the compensatory arrangements for the new director, Mr. Wehrly:
- Annual Retainer: NIS 83,480 (approximately $21,050).
- Meeting Fees: NIS 4,390 (approx. $1,130) for in-person meetings; 60% for telephonic meetings; 50% for unanimous written consents.
- Stock Options (Upfront): Options to purchase 12,546 ordinary shares.
- Stock Options (Annual): Options to purchase 4,176 ordinary shares.
- Background: Mr. Wehrly brings extensive experience from senior roles at Covidien plc, Medtronic, and DePuy (Johnson & Johnson), with a focus on regulatory approval and reimbursement strategies.
Investor Verification Checklist
- Verify the independence status of Peter L. Wehrly against current Nasdaq listing standards.
- Confirm the total number of outstanding options granted to Mr. Wehrly and their impact on dilution.
- Review the Company's subsequent filings to assess the impact of the new Audit Committee member on financial oversight.
- Check for any undisclosed relationships between Mr. Wehrly and other directors or officers as per Item 404(a) of Regulation S-K.